Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
Recruiting
Observational Study
Allergic Bronchopulmonary Aspergillosis (ABPA)
Machine Learning
Multi-omics
Multicenter Study
Relapse
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Qianfoshan Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female and Male patients aged 18-80 years
* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria
Exclusion Criteria:
* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, rena…
Contacts